preDiCT

Many drugs fail to reach the market because of side effects on the heart. The principal objective of this proposal is to create an advanced computational technology for in silico assessment of the efficacy and safety of specific drugs [ICT-2007.5.3(c) (3)], i.e. an open environment comprising validated computational models, tools and numerical methods that will enable simulations of drug actions on the electrophysiology of the human heart.

Such simulations will involve modelling of drug interactions at the molecular and cellular level, will extend current technology to enable prediction of the effects of those interactions on the dynamics of the whole heart, and will lead to an understanding of how genetic factors can be used to assess patient-specific risk profiles. This requires a multi-level systems approach, based on multi-scale, multi-physics methods, including computations on adaptive spatial grids and multi-grid time integration. Computations on realistic models at appropriate spatial and temporal scales are currently not feasible, so we will investigate new algorithms and their implementation on high-performance platforms, including a new generation of petaflop computers, to achieve 'faster than real-time' simulation.

These tools form part of the infrastructure required to simulate the physiology of major organ systems, thereby contributing to the goal of creating the Virtual Physiological Human (VPH) [ICT-2007.5.3]. The balanced team in this project, including founders of the Human Physiome Project, has decades of experience in the experimental study and modelling of the electrophysiology and mechanics of the heart, while pharmaceutical industry partners bring deep understanding of the mechanisms of drug actions. The results will demonstrate the value of the VPH initiative to fundamental scientific understanding of the heart, with major economic and clinical impacts through accelerated drug development, approval and use.

For further information, please visit:
http://www.vph-predict.eu

Project co-ordinator:
The Chancellor, Master and Scholars of the University of Oxford

Partners:

  • F. Hoffmann-La Roche AG
  • Szegedi Tudományegyetem
  • Fujitsu Laboratories of Europe Limited
  • Glaxo Smithkline Research and Development
  • Universidad Politécnica de Valencia
  • Centro di Ricerca, Sviluppo e Studi Superiori in Sardegna
  • Novartis Pharma AG
  • Aureus Pharma SA

Timetable: from 06/2008 – to 05/2011

Total cost: € 5.545.692

EC funding: € 4.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Contact Tracing Apps Unlikely to Contain…

Contract tracing apps used to reduce the spread of COVID-19 are unlikely to be effective without proper uptake and support from concurrent control measures, finds a new study by UCL...

Philips Launches New Innovations to Help…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today presented new approaches to health and healthcare, and the shift to health-at-home, at its virtual consumer health...

Internet Searches for Anxiety Attacks Ta…

Many health experts are concerned that the COVID-19 pandemic could be having widespread effects on people's mental health, but assessing these concerns is difficult without data. "Traditional public health surveillance lacks...

Orion Health Secures Place on Emerging T…

Remote Patient Monitoring solution included on Crown Commercial Services Spark: Technology Innovation Marketplace. Healthcare organisations now have a simple route to procure personalised monitoring for people living with chronic conditions to...

Scientists Develop Low-Cost Chip to Dete…

Robust and widespread antibody testing has emerged as a key strategy in the fight against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. However current testing methods are too inaccurate...

Newly Merged CCG Expands Tech Support to…

Norfolk and Waveney Clinical Commissioning Group to support prescribers to improve the quality and safety of prescribing through deploying prescribing decision technology FDB OptimiseRx. A newly merged clinical commissioning group...

Anonymized Cell Phone Location Data can …

In March 2020, federal officials declared the COVID-19 outbreak a national emergency. Around the same time, most states implemented stay-at-home advisories - to different degrees and at different times. Publicly...

Designed Antiviral Proteins Inhibit SARS…

Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19. The findings are reported today in Science. In the experiments, the lead...

Telehealth Scales Up During the Pandemic…

Hailed for its ability to erase distance between health care providers in cities and patients in rural areas, telehealth has ironically enabled medical care to continue in a time when...

Fitbit Receives Regulatory Clearance in …

Fitbit (NYSE:FIT) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as well as Conformité Européenne (CE) marking in the European Union, for its electrocardiogram (ECG) app...

Don't Fall for the 'Next Best Action' Tr…

15 September, 2020. London, UK. OKRA has announced a new, free webinar called 'Why Next Best Action is not enough', a panel will discuss the urgent need to move beyond the...

Cerner Chosen to Support Population Heal…

Cerner Corporation is pleased to announce a new relationship with Hampshire and Isle of Wight (HIOW) health and care system to enable their population health management journey to transform the...